129 related articles for article (PubMed ID: 38653155)
1. Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort.
Remon J; Auclin E; Zubiri L; Schneider S; Rodriguez-Abreu D; Minatta N; Gautschi O; Aboubakar F; Muñoz-Couselo E; Pierret T; Rothschild SI; Cortiula F; Reynolds KL; Thibault C; Gavralidis A; Blais N; Barlesi F; Planchard D; Besse BMD
ESMO Open; 2024 May; 9(5):103004. PubMed ID: 38653155
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
4. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Tsung I; Worden FP; Fontana RJ
Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
[TBL] [Abstract][Full Text] [Related]
5. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
Bolte LA; Lee KA; Björk JR; Leeming ER; Campmans-Kuijpers MJE; de Haan JJ; Vila AV; Maltez-Thomas A; Segata N; Board R; Harries M; Lorigan P; de Vries EGE; Nathan P; Fehrmann R; Bataille V; Spector TD; Hospers GAP; Weersma RK
JAMA Oncol; 2023 May; 9(5):705-709. PubMed ID: 36795408
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review.
d'Izarny-Gargas T; Durrbach A; Zaidan M
Am J Transplant; 2020 Sep; 20(9):2457-2465. PubMed ID: 32027461
[TBL] [Abstract][Full Text] [Related]
7. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study.
Carroll RP; Boyer M; Gebski V; Hockley B; Johnston JK; Kireta S; Tan H; Taylor A; Wyburn K; Zalcberg JR
Lancet Oncol; 2022 Aug; 23(8):1078-1086. PubMed ID: 35809595
[TBL] [Abstract][Full Text] [Related]
9. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
Pierro M; Baldini C; Auclin E; Vincent H; Varga A; Martin Romano P; Vuagnat P; Besse B; Planchard D; Hollebecque A; Champiat S; Marabelle A; Michot JM; Massard C; Mezquita L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291861
[TBL] [Abstract][Full Text] [Related]
10. Evaluation safety and efficacy of immune checkpoint blockers (ICB) and radiotherapy combination versus ICB in non-small cell lung cancer patients with recurrence or metastasis: A systematic review and meta-analysis.
Zeng Y; Zhang L; Liang Y; Zhang X; Li L; Wang M; Guo J; Li Q; Cao J; Gu JJ; Wang B
Cancer Med; 2023 Jul; 12(13):13928-13941. PubMed ID: 37323098
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
Kotecha RR; Doshi SD; Knezevic A; Chaim J; Chen Y; Jacobi R; Zucker M; Reznik E; McHugh D; Shah NJ; Feld E; Aggen DH; Rafelson W; Xiao H; Carlo MI; Feldman DR; Lee CH; Motzer RJ; Voss MH
Eur Urol Oncol; 2023 Nov; ():. PubMed ID: 37945488
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C; Cassier P; Zamarin D; Machiels JP; Perez Gracia JL; Stephen Hodi F; Taus A; Martinez Garcia M; Boni V; Eder JP; Hafez N; Sullivan R; Mcdermott D; Champiat S; Aspeslagh S; Terret C; Jegg AM; Jacob W; Cannarile MA; Ries C; Korski K; Michielin F; Christen R; Babitzki G; Watson C; Meneses-Lorente G; Weisser M; Rüttinger D; Delord JP; Marabelle A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577503
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A
Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163
[TBL] [Abstract][Full Text] [Related]
15. CD8
Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
[TBL] [Abstract][Full Text] [Related]
16. Sex and organ-specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID-19.
Vinson AJ; Dai R; Agarwal G; Anzalone AJ; Lee SB; French E; Olex AL; Madhira V; Mannon RB;
Am J Transplant; 2022 Jan; 22(1):245-259. PubMed ID: 34637599
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
[TBL] [Abstract][Full Text] [Related]
18. Sepsis outcomes in solid organ transplant recipients.
Gotur DB; Masud FN; Ezeana CF; Nisar T; Paranilam J; Chen S; Puppala M; Wong STC; Zimmerman JL
Transpl Infect Dis; 2020 Feb; 22(1):e13214. PubMed ID: 31755202
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
20. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
